SAB Biotherapeutics
Clinical-stage biopharmaceutical company developing multi-specific, fully human polyclonal immunoglobulin G therapeutics using a genetically engineered transchromosomic livestock platform. Focus areas include disease-modifying immunotherapies for autoimmune disease (notably type 1 diabetes) and rapid-response antibody therapeutics for infectious disease. The organization advances programs through preclinical studies and Phase 1–3 clinical trials, operates clinical and commercial-scale manufacturing programs, and maintains collaborations with U.S. government agencies and commercial partners for pandemic response and development support.
Industries
Nr. of Employees
medium (51-250)
SAB Biotherapeutics
Patents
Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
US-11975066-B2
View Details
Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
US-11975066-B2
View DetailsProducts
SAB-142
Multi‑specific, fully human anti‑thymocyte globulin polyclonal immunotherapy in clinical development as a potential disease‑modifying treatment to delay onset and progression of Stage 3 type 1 diabetes.
SAB-185
Fully human, broadly neutralizing polyclonal antibody therapeutic candidate developed for treatment of COVID‑19; advanced through Phase 2/3 adaptive platform clinical trials and evaluated for neutralization across variants.
SAB-176
Multivalent, broadly neutralizing fully human polyclonal antibody candidate developed for treatment or prevention of Type A and B seasonal and pandemic influenza.
SAB-142
Multi‑specific, fully human anti‑thymocyte globulin polyclonal immunotherapy in clinical development as a potential disease‑modifying treatment to delay onset and progression of Stage 3 type 1 diabetes.
SAB-185
Fully human, broadly neutralizing polyclonal antibody therapeutic candidate developed for treatment of COVID‑19; advanced through Phase 2/3 adaptive platform clinical trials and evaluated for neutralization across variants.
SAB-176
Multivalent, broadly neutralizing fully human polyclonal antibody candidate developed for treatment or prevention of Type A and B seasonal and pandemic influenza.
Services
Partnership development and contract execution to advance rapid‑response antibody programs, clinical development, and manufacturing scale‑up.
Partnership development and contract execution to advance rapid‑response antibody programs, clinical development, and manufacturing scale‑up.
Expertise Areas
- Polyclonal antibody therapeutics
- Immunotherapy for autoimmune diseases (type 1 diabetes)
- Rapid-response pandemic antibody development
- Clinical trial management (Phase 1–3, adaptive/multi-center protocols)
Key Technologies
- Transchromosomic livestock-derived human antibody production
- Polyclonal antibody platform technologies
- Pseudovirus neutralization assays
- qRT-PCR viral load assays
News & Updates
Company management participated in an investor healthcare conference (management presentation).
Presentation of Phase 1 encore data highlighting mechanism of action, redosing potential, and early C‑peptide response for SAB-142.
Government contract awarded to develop a novel rapid‑response antibody production and capability for the U.S. Department of Defense.
Public announcement of a collaborative agreement with a commercial biologics manufacturer to support development and delivery of an antibody therapeutic candidate.
First‑in‑human (Phase I) clinical trials underway for a candidate treatment targeting MERS coronavirus.
Announcement that FDA granted Fast Track designation to the investigational multi‑specific hATG therapy for Stage 3 T1D.
Company management participated in an investor healthcare conference (management presentation).
Presentation of Phase 1 encore data highlighting mechanism of action, redosing potential, and early C‑peptide response for SAB-142.
Government contract awarded to develop a novel rapid‑response antibody production and capability for the U.S. Department of Defense.
Public announcement of a collaborative agreement with a commercial biologics manufacturer to support development and delivery of an antibody therapeutic candidate.
First‑in‑human (Phase I) clinical trials underway for a candidate treatment targeting MERS coronavirus.
Announcement that FDA granted Fast Track designation to the investigational multi‑specific hATG therapy for Stage 3 T1D.